Investors

Investor Relations

Investor Relations

Allakos is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. Our initial clinical focus is eosinophilic gastritis, an inflammatory disease of the gastrointestinal tract. We are also conducting clinical trials for other mast cell and eosinophil-driven diseases including chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.

Copyright West LLC. Minimum 15 minutes delayed.